Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
A trial of fludarabine and cyclophosphamide followed by thalidomide for angioimmunoblastic lymphoma
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This trial was for people just diagnosed with a rare type of non Hodgkin lymphoma called angioimmunoblastic lymphoma.
Cancer Research UK supported this trial.
More about this trial
CHOP chemotherapy is the usual treatment for angioimmunoblastic lymphoma. But compared to other types of lymphoma the outlook (
In this trial they looked at a combination of 2 chemotherapy drugs called fludarabine and cyclophosphamide. This drug combination has been used to treat other types of lymphoma. But doctors didn’t know how well it would work for angioimmunoblastic lymphoma.
They also looked at a type of
The aims of the trial were to:
- see if fludarabine and cyclophosphamide helped people with angioimmunoblastic lymphoma
- find if having thalidomide after chemotherapy also helped
- learn more about the side effects
Summary of results
The trial team found that fludarabine and cyclophosphamide followed by thalidomide shouldn’t be used as a
This was a phase 2 trial.
Everyone had fludarabine and cyclophosphamide followed by thalidomide.
15 people joined the trial. The team were able to look at the results of 13 people.
When the researchers looked at how well the fludarabine and cyclophosphamide worked they found that for:
- 6 people there was no sign of their lymphoma (
- 3 people their lymphoma had shrunk (
- 4 people their lymphoma got worse
7 people went on to have thalidomide after chemotherapy.
- 4 people’s lymphoma got worse
- 3 people’s lymphoma didn’t get any better or any worse
The average length of time people lived without their lymphoma coming back was 5 ½ months.
The average length of time people lived after treatment was just under 15 months.
The worst side effects of fludarabine and cyclophosphamide included:
- a drop in blood cells
- tiredness (physically and mentally)
The worst side effects of thalidomide included:
- a drop in blood cells
- lung infection (pneumonia)
The trial team concluded that fludarabine and cyclophosphamide followed by thalidomide didn’t work well for people with angioimmumoblastic lymphoma.
There is no
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Dr Claudius Rudin
Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
This is Cancer Research UK trial number CRUK/06/023.